Fremanezumab ( DrugBank: Fremanezumab )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
124	Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy	1
226	Interstitial cystitis with Hunners ulcer	1

124. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy

---

Clinical trials : 12 /  Drugs : 14 - (DrugBank : 5) / Drug target genes : 6 - Drug target pathways : 23

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04334408 (ClinicalTrials.gov)	December 2021	2/4/2020	Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL	A Phase II Double-Blinded Placebo Controlled Individual Subject Stepped Wedge Clinical Trial Evaluating the Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL	Cadasil;Migraine	Drug: Fremanezumab;Drug: Placebo	Mayo Clinic	NULL	Not yet recruiting	18 Years	70 Years	All	5	Phase 2	United States

226. Interstitial cystitis with Hunners ulcer

---

Clinical trials : 143 /  Drugs : 171 - (DrugBank : 56) / Drug target genes : 64 - Drug target pathways : 145

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04447729 (ClinicalTrials.gov)	October 15, 2020	10/6/2020	A Study to Test if Fremanezumab Reduces Pain in Patients With Interstitial Cystitis-Bladder Pain Syndrome	A Multicenter, Open-label Pilot Study of the Efficacy and Safety of Fremanezumab for Treatment of Female Patients With Interstitial Cystitis-Bladder Pain Syndrome	Interstitial Cystitis	Drug: fremanezumab	Teva Branded Pharmaceutical Products R&D, Inc.	NULL	Withdrawn	18 Years	N/A	Female	0	Phase 2	NULL